AR and neoplasm: Indeed, some studies demonstrated that the PI3K/AKT pathway (49%) is the third most frequently mutated, only behind the androgen receptor (AR) (70%) and TP53 (53%) in metastatic CRPC compared to primary tumour, which has improved the understanding and precision treatment of metastatic CRPC [4].